Related Experiment Video
Updated: Mar 31, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
Monoclonal antibody desensitization in a patient with a generalized urticarial reaction following denosumab
D Gutiérrez-Fernández1, María-Jesús Cruz2, A Foncubierta-Fernández3
1Pneumology-Allergy Department, Puerta del Mar University Hospital, Cádiz, Spain.
Abstract:
Denosumab is a human monoclonal antibody indicated for the treatment of osteoporosis in postmenopausal women with a high risk of fractures. To our knowledge, no cases of desensitization to this drug have been described in the literature. We report the first case of generalized urticarial reaction and facial angioedema after therapy with denosumab. A subcutaneous desensitization protocol was successfully completed in this patient. Rapid desensitization is a promising method for the delivery of denosumab after a hypersensitivity reaction, and should be considered in osteoporosis treatment when no acceptable therapeutic alternatives are available.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Hypersensitivity Reactions: Immune-Complex Reactions
Allergic Reactions: Anaphylaxis
Hypersensitivity Reactions: Cytolytic Reactions
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Desensitization and Tachyphylaxis

